{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:36:08Z","timestamp":1794350168725,"version":"4.9.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012352","name":"Universit\u00e0 degli Studi di Milano","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40265-025-02194-w","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T07:21:36Z","timestamp":1746861696000},"page":"855-866","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Role of CPX-351 in the Acute Myeloid Leukemia Treatment Landscape: Mechanism of Action, Efficacy, and Safety"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8287-928X","authenticated-orcid":false,"given":"Livio","family":"Pagano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4414-8934","authenticated-orcid":false,"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5295-2087","authenticated-orcid":false,"given":"Edoardo","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9672-2733","authenticated-orcid":false,"given":"Riccardo","family":"Morgagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1356-525X","authenticated-orcid":false,"given":"Luigina","family":"Romani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0245-0553","authenticated-orcid":false,"given":"Adriano","family":"Venditti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"issue":"12","key":"2194_CR1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136\u201352.","journal-title":"N Engl J Med"},{"key":"2194_CR2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40164-020-00170-6","volume":"9","author":"Y Dong","year":"2020","unstructured":"Dong Y, Shi O, Zeng Q, Lu X, Wang W, Li Y, et al. Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Exp Hematol Oncol. 2020;9:14.","journal-title":"Exp Hematol Oncol"},{"key":"2194_CR3","volume":"9","author":"CT Jani","year":"2023","unstructured":"Jani CT, Ahmed A, Singh H, Mouchati C, Al Omari O, Bhatt PS, et al. Burden of AML, 1990\u20132019: estimates from the Global Burden of Disease Study. JCO Glob Oncol. 2023;9:e2300229.","journal-title":"JCO Glob Oncol"},{"key":"2194_CR4","doi-asserted-by":"crossref","first-page":"102549","DOI":"10.1016\/j.eclinm.2024.102549","volume":"71","author":"MS Linet","year":"2024","unstructured":"Linet MS, Curtis RE, Schonfeld SJ, Vo JB, Morton LM, Dores GM. Survival of adult AML patients treated with chemotherapy in the US population by age, race and ethnicity, sex, calendar-year period, and AML subgroup, 2001\u20132019. EClinicalMedicine. 2024;71:102549.","journal-title":"EClinicalMedicine"},{"issue":"12","key":"2194_CR5","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s00277-017-3150-3","volume":"96","author":"G Nagel","year":"2017","unstructured":"Nagel G, Weber D, Fromm E, Erhardt S, L\u00fcbbert M, Fiedler W, et al. Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Ann Hematol. 2017;96(12):1993\u20132003.","journal-title":"Ann Hematol"},{"issue":"3","key":"2194_CR6","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.23908","volume":"90","author":"E Huleg\u00e5rdh","year":"2015","unstructured":"Huleg\u00e5rdh E, Nilsson C, Lazarevic V, Garelius H, Antunovic P, Rangert Derolf \u00c5, et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2015;90(3):208\u201314.","journal-title":"Am J Hematol"},{"issue":"4","key":"2194_CR7","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1182\/bloodadvances.2021005335","volume":"6","author":"D Mart\u00ednez-Cuadr\u00f3n","year":"2022","unstructured":"Mart\u00ednez-Cuadr\u00f3n D, Meg\u00edas-Vericat JE, Serrano J, Mart\u00ednez-S\u00e1nchez P, Rodr\u00edguez-Arbol\u00ed E, Gil C, et al. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Blood Adv. 2022;6(4):1278\u201395.","journal-title":"Blood Adv"},{"issue":"12","key":"2194_CR8","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"6","key":"2194_CR9","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.annonc.2020.02.018","volume":"31","author":"M Heuser","year":"2020","unstructured":"Heuser M, Ofran Y, Boissel N, Brunet Mauri S, Craddock C, Janssen J, et al. Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(6):697\u2013712.","journal-title":"Ann Oncol"},{"issue":"2","key":"2194_CR10","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bjh.17746","volume":"196","author":"S Kayser","year":"2022","unstructured":"Kayser S, Levis MJ. Updates on targeted therapies for acute myeloid leukaemia. Br J Haematol. 2022;196(2):316\u201328.","journal-title":"Br J Haematol"},{"issue":"1","key":"2194_CR11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","volume":"16","author":"RS Bhansali","year":"2023","unstructured":"Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 2023;16(1):29.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2194_CR12","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11912-024-01503-y","volume":"26","author":"M Wysota","year":"2024","unstructured":"Wysota M, Konopleva M, Mitchell S. Novel therapeutic targets in acute myeloid leukemia (AML). Curr Oncol Rep. 2024;26(4):409\u201320.","journal-title":"Curr Oncol Rep"},{"issue":"17","key":"2194_CR13","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1182\/bloodadvances.2024013102","volume":"8","author":"H Liu","year":"2024","unstructured":"Liu H, Stanworth SJ, McPhail S, Bishton M, Rous B, Bacon A, et al. Impact of patient demographics on treatment outcomes in AML: a population-based registry in England, 2013\u20132020. Blood Adv. 2024;8(17):4593\u2013605.","journal-title":"Blood Adv"},{"issue":"4","key":"2194_CR14","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347.","journal-title":"Blood"},{"issue":"1","key":"2194_CR15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/hematology.2019000006","volume":"2019","author":"J Cloos","year":"2019","unstructured":"Cloos J, Ossenkoppele GJ, Dillon R. Minimal residual disease and stem cell transplantation outcomes. Hematol Am Soc Hematol Educ Program. 2019;2019(1):617\u201325.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"22","key":"2194_CR16","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood.V128.22.901.901","volume":"128","author":"G Garcia-Manero","year":"2016","unstructured":"Garcia-Manero G, Othus M, Pagel JM, Radich JP, Fang M, Rizzieri DA, et al. SWOG S1203: a randomized phase iii study of standard cytarabine plus daunorubicin (7 + 3) therapy versus idarubicin with high dose cytarabine (IA) with or without vorinostat (IA + V) in younger patients with previously untreated acute myeloid leukemia (AML). Blood. 2016;128(22):901.","journal-title":"Blood"},{"issue":"13","key":"2194_CR17","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","volume":"361","author":"B L\u00f6wenberg","year":"2009","unstructured":"L\u00f6wenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235\u201348.","journal-title":"N Engl J Med"},{"issue":"5","key":"2194_CR18","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cncr.21723","volume":"106","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, O\u2019Brien S, Cortes J, Giles F, Faderl S, Jabbour E, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106(5):1090\u20138.","journal-title":"Cancer"},{"issue":"18","key":"2194_CR19","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","volume":"113","author":"G Juliusson","year":"2009","unstructured":"Juliusson G, Antunovic P, Derolf A, Lehmann S, M\u00f6llg\u00e5rd L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179\u201387.","journal-title":"Blood"},{"issue":"10","key":"2194_CR20","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1182\/blood-2007-06-095844","volume":"110","author":"E Atallah","year":"2007","unstructured":"Atallah E, Cortes J, O\u2019Brien S, Pierce S, Rios MB, Estey E, et al. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood. 2007;110(10):3547\u201351.","journal-title":"Blood"},{"issue":"8","key":"2194_CR21","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1182\/bloodadvances.2020001728","volume":"4","author":"AM Zeidan","year":"2020","unstructured":"Zeidan AM, Podoltsev NA, Wang X, Zhang C, Bewersdorf JP, Shallis RM, et al. Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States. Blood Adv. 2020;4(8):1615\u201323.","journal-title":"Blood Adv"},{"issue":"4","key":"2194_CR22","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, D\u00f6hner H, et al. Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99(4):615\u201324.","journal-title":"Am J Hematol"},{"key":"2194_CR23","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration Oncology Center of Excellence, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research. Guidance for industry: acute myeloid leukemia: developing drugs and biological products for treatment. 2022. https:\/\/www.fda.gov\/media\/162362\/download. Accessed 2 Sept 2024."},{"key":"2194_CR24","doi-asserted-by":"crossref","first-page":"204062072098664","DOI":"10.1177\/2040620720986646","volume":"12","author":"I Aldoss","year":"2021","unstructured":"Aldoss I, Pullarkat V, Stein AS. Venetoclax-containing regimens in acute myeloid leukemia. Ther Adv Hematol. 2021;12:2040620720986646.","journal-title":"Ther Adv Hematol."},{"issue":"7","key":"2194_CR25","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"2194_CR26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood-2020-134832","volume":"136","author":"KW Pratz","year":"2020","unstructured":"Pratz KW, DiNardo CD, Selleslag D, Li J, Yamamoto K, Konopleva M, et al. Cytopenia management in patients with newly diagnosed acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study. Blood. 2020;136(Suppl 1):51\u20133.","journal-title":"Blood"},{"issue":"12","key":"2194_CR27","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1517\/17425247.2010.538678","volume":"7","author":"A Dicko","year":"2010","unstructured":"Dicko A, Mayer LD, Tardi PG. Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo. Expert Opin Drug Deliv. 2010;7(12):1329\u201341.","journal-title":"Expert Opin Drug Deliv"},{"issue":"13","key":"2194_CR28","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2217\/fon-2017-0607","volume":"14","author":"AW Tolcher","year":"2018","unstructured":"Tolcher AW, Mayer LD. Improving combination cancer therapy: the CombiPlex\u00ae development platform. Future Oncol. 2018;14(13):1317\u201332.","journal-title":"Future Oncol"},{"issue":"7","key":"2194_CR29","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1158\/1535-7163.MCT-06-0118","volume":"5","author":"LD Mayer","year":"2006","unstructured":"Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther. 2006;5(7):1854\u201363.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"2194_CR30","doi-asserted-by":"crossref","first-page":"9518","DOI":"10.1021\/nn405674m","volume":"7","author":"L Ma","year":"2013","unstructured":"Ma L, Kohli M, Smith A. Nanoparticles for combination drug therapy. ACS Nano. 2013;7(11):9518\u201325.","journal-title":"ACS Nano"},{"issue":"1","key":"2194_CR31","first-page":"34","volume":"16","author":"BD Liboiron","year":"2016","unstructured":"Liboiron BD, Louie AC, Mayer LD. Nanoscale complexes: a novel nanotechnology-based platform to optimize combination cancer therapies: rational development & improved delivery using CombiPlex\u00ae. Drug Dev Deliv. 2016;16(1):34\u20139.","journal-title":"Drug Dev Deliv"},{"key":"2194_CR32","unstructured":"VYXEOS\u00ae (daunorubincin and cytarabine) liposome for injection, for intravenous use [prescribing information]. Palo Alto: Jazz Pharmaceuticals, Inc.; 2022."},{"key":"2194_CR33","unstructured":"VYXEOS\u00ae (daunorubicin and cytarabine liposome for injection) product monograph. Mississauga: Jazz Pharmaceuticals Canada, Inc.; 2023."},{"key":"2194_CR34","unstructured":"Vyxeos liposomal (44 mg\/100 mg powder for concentrate for solution for infusion) summary of product characteristics. European Medicines Agency: Jazz Pharmaceuticals Ireland, Ltd.; 2024."},{"key":"2194_CR35","unstructured":"Vyxeos liposomal (44 mg\/100 mg powder for concentrate for solution for infusion) summary of product characteristics. Electronic Medicines Compendium: Jazz Pharmaceuticals UK, Ltd.; 2025."},{"issue":"26","key":"2194_CR36","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684\u201392.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2194_CR37","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","volume":"8","author":"JE Lancet","year":"2021","unstructured":"Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, et al. CPX-351 versus 7 + 3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021;8(7):e481\u201391.","journal-title":"Lancet Haematol."},{"issue":"9","key":"2194_CR38","doi-asserted-by":"crossref","first-page":"e1414","DOI":"10.1634\/theoncologist.2019-0785","volume":"25","author":"K Tzogani","year":"2020","unstructured":"Tzogani K, Penttil\u00e4 K, Lapvetel\u00e4inen T, Hemmings R, Koenig J, Freire J, et al. EMA review of daunorubicin and cytarabine encapsulated in liposomes (Vyxeos, CPX-351) for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes. Oncologist. 2020;25(9):e1414\u201320.","journal-title":"Oncologist"},{"issue":"10","key":"2194_CR39","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1016\/j.clml.2023.07.003","volume":"23","author":"A Legg","year":"2023","unstructured":"Legg A, Lambova A, Broe A, Levy J, Medalla G. Real-world experience with CPX-351 treatment for acute myeloid leukemia in England: an analysis from the national cancer registration and analysis service. Clin Lymphoma Myeloma Leuk. 2023;23(10):e323\u201330.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2194_CR40","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/bjh.19622","volume":"205","author":"P Mehta","year":"2024","unstructured":"Mehta P, Campbell V, Maddox J, Floisand Y, Kalakonda AJM, O\u2019Nions J, et al. CREST-UK: real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK. Br J Haematol. 2024;205(4):1326\u201336.","journal-title":"Br J Haematol"},{"issue":"10","key":"2194_CR41","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41408-021-00558-5","volume":"11","author":"C Rautenberg","year":"2021","unstructured":"Rautenberg C, St\u00f6lzel F, R\u00f6llig C, Stelljes M, Gaidzik V, Lauseker M, et al. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. Blood Cancer J. 2021;11(10):164.","journal-title":"Blood Cancer J"},{"issue":"1","key":"2194_CR42","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/bloodadvances.2020003159","volume":"5","author":"E Chiche","year":"2021","unstructured":"Chiche E, Rahm\u00e9 R, Bertoli S, Dumas P-Y, Micol J-B, Hicheri Y, et al. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. Blood Adv. 2021;5(1):176\u201384.","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"2194_CR43","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood-2023-189025","volume":"142","author":"F Guolo","year":"2023","unstructured":"Guolo F, Fianchi L, Martelli MP, Chiusolo P, Lussana F, Grimaldi F, et al. Optimal duration of CPX-351 treatment and best timing for consolidation with allogeneic stem cell transplantation: evidence from a large real-world Italian study. Blood. 2023;142(Supplement 1):731.","journal-title":"Blood"},{"issue":"10","key":"2194_CR44","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41408-020-00361-8","volume":"10","author":"F Guolo","year":"2020","unstructured":"Guolo F, Fianchi L, Minetto P, Clavio M, Gottardi M, Galimberti S, et al. CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood Cancer J. 2020;10(10):96.","journal-title":"Blood Cancer J"},{"issue":"16","key":"2194_CR45","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood.2023021380","volume":"143","author":"G Renga","year":"2024","unstructured":"Renga G, Nunzi E, Stincardini C, Pariano M, Puccetti M, Pieraccini G, et al. CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization resistance, and immune homeostasis. Blood. 2024;143(16):1628\u201345.","journal-title":"Blood"},{"issue":"13","key":"2194_CR46","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.3390\/cancers15133457","volume":"15","author":"L Fianchi","year":"2023","unstructured":"Fianchi L, Guolo F, Marchesi F, Cattaneo C, Gottardi M, Restuccia F, et al. Multicenter observational retrospective study on febrile events in patients with acute myeloid leukemia treated with Cpx-351 in \u201creal-life\u201d: the SEIFEM experience. Cancers (Basel). 2023;15(13):3457.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"2194_CR47","doi-asserted-by":"crossref","first-page":"21054","DOI":"10.1038\/s41598-023-47293-4","volume":"13","author":"MC Fortin","year":"2023","unstructured":"Fortin MC, LaCroix AS, Grammatopoulos TN, Tan L, Wang Q, Manca D. Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro. Sci Rep. 2023;13(1):21054.","journal-title":"Sci Rep"},{"issue":"8","key":"2194_CR48","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1200\/JCO.2010.30.5961","volume":"29","author":"EJ Feldman","year":"2011","unstructured":"Feldman EJ, Lancet JE, Kolitz JE, Ritchie EK, Roboz GJ, List AF, et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol. 2011;29(8):979\u201385.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2194_CR49","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.leukres.2012.07.006","volume":"36","author":"EJ Feldman","year":"2012","unstructured":"Feldman EJ, Kolitz JE, Trang JM, Liboiron BD, Swenson CE, Chiarella MT, et al. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk Res. 2012;36(10):1283\u20139.","journal-title":"Leuk Res"},{"issue":"1","key":"2194_CR50","doi-asserted-by":"crossref","first-page":"1800897","DOI":"10.1080\/19490976.2020.1800897","volume":"12","author":"T Hueso","year":"2020","unstructured":"Hueso T, Ekpe K, Mayeur C, Gatse A, Joncquel-Chevallier Curt M, Gricourt G, et al. Impact and consequences of intensive chemotherapy on intestinal barrier and microbiota in acute myeloid leukemia: the role of mucosal strengthening. Gut Microbes. 2020;12(1):1800897.","journal-title":"Gut Microbes."},{"issue":"11","key":"2194_CR51","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.clnu.2023.09.021","volume":"42","author":"SA P\u00f6tgens","year":"2023","unstructured":"P\u00f6tgens SA, Lecop S, Havelange V, Li F, Neyrinck AM, Neveux N, et al. Gut microbiota alterations induced by intensive chemotherapy in acute myeloid leukaemia patients are associated with gut barrier dysfunction and body weight loss. Clin Nutr. 2023;42(11):2214\u201328.","journal-title":"Clin Nutr"},{"issue":"11","key":"2194_CR52","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1182\/bloodadvances.2021006783","volume":"6","author":"A Rashidi","year":"2022","unstructured":"Rashidi A, Ebadi M, Rehman TU, Elhusseini H, Halaweish HF, Kaiser T, et al. Lasting shift in the gut microbiota in patients with acute myeloid leukemia. Blood Adv. 2022;6(11):3451\u20137.","journal-title":"Blood Adv"},{"issue":"14","key":"2194_CR53","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1002\/cncr.30039","volume":"122","author":"JR Galloway-Pe\u00f1a","year":"2016","unstructured":"Galloway-Pe\u00f1a JR, Smith DP, Sahasrabhojane P, Ajami NJ, Wadsworth WD, Daver NG, et al. The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer. 2016;122(14):2186\u201396.","journal-title":"Cancer"},{"issue":"10","key":"2194_CR54","volume":"15","author":"T Rattanathammethee","year":"2020","unstructured":"Rattanathammethee T, Tuitemwong P, Thiennimitr P, Sarichai P, Na Pombejra S, Piriyakhuntorn P, et al. Gut microbiota profiles of treatment-na\u00efve adult acute myeloid leukemia patients with neutropenic fever during intensive chemotherapy. PLoS\u00a0One. 2020;15(10):e0236460.","journal-title":"PLoS One"},{"issue":"1","key":"2194_CR55","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41375-019-0547-0","volume":"34","author":"A Rashidi","year":"2020","unstructured":"Rashidi A, Kaiser T, Graiziger C, Holtan SG, Rehman TU, Weisdorf DJ, et al. Specific gut microbiota changes heralding bloodstream infection and neutropenic fever during intensive chemotherapy. Leukemia. 2020;34(1):312\u20136.","journal-title":"Leukemia"},{"issue":"2","key":"2194_CR56","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.diagmicrobio.2012.10.001","volume":"75","author":"D Neofytos","year":"2013","unstructured":"Neofytos D, Lu K, Hatfield-Seung A, Blackford A, Marr KA, Treadway S, et al. Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy. Diagn Microbiol Infect Dis. 2013;75(2):144\u20139.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"S3","key":"2194_CR57","doi-asserted-by":"crossref","first-page":"e178806c","DOI":"10.1097\/01.HS9.0000968972.17880.6c","volume":"7","author":"JD Mitchell","year":"2023","unstructured":"Mitchell JD, Pfeiffer M, Boehmer J, Gorcsan J, Dronamraju N, Faderl S, et al. P516: Cardiotoxicity of CPX-351 vs 7 + 3 in patients with untreated high-risk acute myeloid leukemia. Hemasphere. 2023;7(S3):e178806c.","journal-title":"Hemasphere"},{"issue":"1","key":"2194_CR58","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.leukres.2008.06.028","volume":"33","author":"P Tardi","year":"2009","unstructured":"Tardi P, Johnstone S, Harasym N, Xie S, Harasym T, Zisman N, et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res. 2009;33(1):129\u201339.","journal-title":"Leuk Res"},{"issue":"9","key":"2194_CR59","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.leukres.2010.01.015","volume":"34","author":"WS Lim","year":"2010","unstructured":"Lim WS, Tardi PG, Dos Santos N, Xie X, Fan M, Liboiron BD, et al. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leuk Res. 2010;34(9):1214\u201323.","journal-title":"Leuk Res"},{"key":"2194_CR60","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.leukres.2016.12.002","volume":"53","author":"MJ Gordon","year":"2017","unstructured":"Gordon MJ, Tardi P, Loriaux MM, Spurgeon SE, Traer E, Kovacsovics T, et al. CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. Leuk Res. 2017;53:39\u201349.","journal-title":"Leuk Res"},{"key":"2194_CR61","volume":"30","author":"Q Wang","year":"2020","unstructured":"Wang Q, Tardi P, Sadowski N, Xie S, Heller D, Mayer L. Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals. Nanomedicine. 2020;30:102275.","journal-title":"Nanomedicine"},{"key":"2194_CR62","unstructured":"US Food and Drug Administration. FDA approves first treatment for certain types of poor-prognosis acute myeloid leukemia. 2017. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-certain-types-poor-prognosis-acute-myeloid-leukemia. Accessed December 2024."},{"key":"2194_CR63","unstructured":"Jazz Pharmaceuticals. Jazz Pharmaceuticals secures eight additional provincial reimbursements for Vyxeos\u00ae for treatment of adults with newly diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes. 2023. https:\/\/investor.jazzpharma.com\/news-releases\/news-release-details\/jazz-pharmaceuticals-secures-eight-additional-provincial. Accessed December 2024."},{"key":"2194_CR64","unstructured":"National Institute for Health and Care Excellence. Liposomal cytarabine\u2013daunorubicin for untreated acute myeloid leukaemia. 2018. https:\/\/www.nice.org.uk\/guidance\/ta552\/chapter\/2-Information-about-liposomal-cytarabinedaunorubicin. Accessed December 2024."},{"issue":"13","key":"2194_CR65","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","volume":"6","author":"AH Matthews","year":"2022","unstructured":"Matthews AH, Perl AE, Luger SM, Loren AW, Gill SI, Porter DL, et al. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv. 2022;6(13):3997\u20134005.","journal-title":"Blood Adv"},{"issue":"9","key":"2194_CR66","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1056\/NEJMoa1900623","volume":"382","author":"JU Peled","year":"2020","unstructured":"Peled JU, Gomes ALC, Devlin SM, Littmann ER, Taur Y, Sung AD, et al. Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation. New Engl J Med. 2020;382(9):822\u201334.","journal-title":"New Engl J Med."},{"issue":"6","key":"2194_CR67","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.chom.2024.05.002","volume":"32","author":"S Woelfel","year":"2024","unstructured":"Woelfel S, Silva MS, Stecher B. Intestinal colonization resistance in the context of environmental, host, and microbial determinants. Cell Host Microbe. 2024;32(6):820\u201336.","journal-title":"Cell Host Microbe"},{"key":"2194_CR68","volume":"137","author":"Z Li","year":"2024","unstructured":"Li Z, Wan M, Wang M, Duan J, Jiang S. Modulation of gut microbiota on intestinal permeability: a novel strategy for treating gastrointestinal related diseases. Int Immunopharmacol. 2024;137:112416.","journal-title":"Int Immunopharmacol"},{"issue":"17","key":"2194_CR69","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood.2023021174","volume":"143","author":"J Fernandez Sanchez","year":"2024","unstructured":"Fernandez Sanchez J, Maknojia AA, King KY. Blood and guts: how the intestinal microbiome shapes hematopoiesis and treatment of hematologic disease. Blood. 2024;143(17):1689\u2013701.","journal-title":"Blood"},{"issue":"8","key":"2194_CR70","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41575-021-00430-8","volume":"18","author":"B Stockinger","year":"2021","unstructured":"Stockinger B, Shah K, Wincent E. AHR in the intestinal microenvironment: safeguarding barrier function. Nat Rev Gastroenterol Hepatol. 2021;18(8):559\u201370.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"2194_CR71","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/ibd\/izad312","volume":"30","author":"C Yang","year":"2024","unstructured":"Yang C, Merlin D. Unveiling colitis: a journey through the dextran sodium sulfate-induced model. Inflamm Bowel Dis. 2024;30(5):844\u201353.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"2194_CR72","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1182\/bloodadvances.2020003510","volume":"5","author":"TL Lin","year":"2021","unstructured":"Lin TL, Rizzieri DA, Ryan DH, Schiller GJ, Kolitz JE, Uy GL, et al. Older adults with newly diagnosed high-risk\/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. Blood Adv. 2021;5(6):1719\u201328.","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"2194_CR73","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.1016\/j.clml.2019.07.084","volume":"19","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Ryan RJ, Chiarella M. Pooled clinical safety analysis of CPX-351 versus conventional chemotherapy in patients with newly diagnosed or relapsed\/refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2019;19(Suppl 1):S214\u20135.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2194_CR74","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/cid\/ciz777","volume":"71","author":"JR Galloway-Pe\u00f1a","year":"2020","unstructured":"Galloway-Pe\u00f1a JR, Shi Y, Peterson CB, Sahasrabhojane P, Gopalakrishnan V, Brumlow CE, et al. Gut microbiome signatures are predictive of infectious risk following induction therapy for acute myeloid leukemia. Clin Infect Dis. 2020;71(1):63\u201371.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2194_CR75","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1038\/s41467-022-30240-8","volume":"13","author":"R Wang","year":"2022","unstructured":"Wang R, Yang X, Liu J, Zhong F, Zhang C, Chen Y, et al. Gut microbiota regulates acute myeloid leukaemia via alteration of intestinal barrier function mediated by butyrate. Nat Commun. 2022;13(1):2522.","journal-title":"Nat Commun"},{"key":"2194_CR76","unstructured":"Fianchi L, Quattrone M, Guolo F, Gottardi M, Farina F, Candoni A, et al. Infectious complications in patients undergoing allogeneic stem cell transplantation (HSCT) for acute myeloid leukemia after CPX-351 treatment: a \u201creal-life\u201d multicenter retrospective experience by the SEIFEM Group. Abstract C044 presented at the 51st National Congress of the Italian Society of Hematology, Milan, Italy, September 23-25, 2024."},{"issue":"2","key":"2194_CR77","doi-asserted-by":"crossref","first-page":"59","DOI":"10.14740\/jh1105","volume":"12","author":"R Babakhanlou","year":"2023","unstructured":"Babakhanlou R, Ravandi-Kashani F, Kontoyiannis DP. Neutropenic enterocolitis: an uncommon, but fearsome complication of leukemia. J Hematol. 2023;12(2):59\u201365.","journal-title":"J Hematol"},{"key":"2194_CR78","doi-asserted-by":"crossref","first-page":"1272072","DOI":"10.3389\/fonc.2023.1272072","volume":"13","author":"E Benedetti","year":"2023","unstructured":"Benedetti E, Traverso G, Pucci G, Morganti R, Bramanti E, Lippolis P, et al. Impact of different chemotherapy regimens on intestinal mucosal injury assessed with bedside ultrasound: a study in 213 AML patients. Front Oncol. 2023;13:1272072.","journal-title":"Front Oncol"},{"key":"2194_CR79","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/1471-2407-10-337","volume":"10","author":"LA Smith","year":"2010","unstructured":"Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337.","journal-title":"BMC Cancer"},{"issue":"22","key":"2194_CR80","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981\u20138.","journal-title":"Circulation"},{"key":"2194_CR81","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","volume":"7","author":"D Cardinale","year":"2020","unstructured":"Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med. 2020;7:26.","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"2194_CR82","first-page":"567","volume":"2","author":"AM Rahman","year":"2007","unstructured":"Rahman AM, Yusuf SW, Ewer MS. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomed. 2007;2(4):567\u201383.","journal-title":"Int J Nanomed"},{"issue":"1","key":"2194_CR83","first-page":"15","volume":"11","author":"F Cai","year":"2019","unstructured":"Cai F, Luis MAF, Lin X, Wang M, Cai L, Cen C, et al. Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: preventive strategies and treatment. Mol Clin Oncol. 2019;11(1):15\u201323.","journal-title":"Mol Clin Oncol."},{"issue":"1","key":"2194_CR84","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00280-019-03856-9","volume":"84","author":"TL Lin","year":"2019","unstructured":"Lin TL, Newell LF, Stuart RK, Michaelis LC, Rubenstein E, Pentikis HS, et al. A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias. Cancer Chemother Pharmacol. 2019;84(1):163\u201373.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"2194_CR85","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jacc.2019.11.059","volume":"75","author":"JM Bonsu","year":"2020","unstructured":"Bonsu JM, Guha A, Charles L, Yildiz VO, Wei L, Baker B, et al. Reporting of cardiovascular events in clinical trials supporting FDA approval of contemporary cancer therapies. J Am Coll Cardiol. 2020;75(6):620\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2194_CR86","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00520-009-0769-1","volume":"18","author":"M Gandhi","year":"2010","unstructured":"Gandhi M, Oishi K, Zubal B, Lacouture ME. Unanticipated toxicities from anticancer therapies: survivors\u2019 perspectives. Support Care Cancer. 2010;18(11):1461\u20138.","journal-title":"Support Care Cancer"},{"issue":"19","key":"2194_CR87","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.3390\/healthcare11192621","volume":"11","author":"V Almeida","year":"2023","unstructured":"Almeida V, Pires D, Silva M, Teixeira M, Teixeira RJ, Louro A, et al. Dermatological side effects of cancer treatment: psychosocial implications\u2014a systematic review of the literature. Healthcare (Basel). 2023;11(19):2621.","journal-title":"Healthcare (Basel)."},{"issue":"4","key":"2194_CR88","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/pon.4039","volume":"26","author":"P Dua","year":"2017","unstructured":"Dua P, Heiland MF, Kracen AC, Deshields TL. Cancer-related hair loss: a selective review of the alopecia research literature. Psychooncology. 2017;26(4):438\u201343.","journal-title":"Psychooncology"},{"issue":"5","key":"2194_CR89","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jaad.2018.03.055","volume":"80","author":"A Freites-Martinez","year":"2019","unstructured":"Freites-Martinez A, Shapiro J, Goldfarb S, Nangia J, Jimenez JJ, Paus R, et al. Hair disorders in cancer patients. J Am Acad Dermatol. 2019;80(5):1179\u201396.","journal-title":"J Am Acad Dermatol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02194-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02194-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02194-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T15:55:40Z","timestamp":1750694140000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02194-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":89,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2194"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02194-w","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,10]]},"assertion":[{"value":"18 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi di Milano within the CRUI-CARE Agreement. Under the direction of the authors, Trina Soluta and Claire Cartledge of CMC Affinity, a division of IPG Health Medical Communications, provided medical writing and editorial support, respectively, which was funded by Jazz Pharmaceuticals in accordance with Good Publication Practice (GPP 2022) guidelines. Jazz Pharmaceuticals reviewed the manuscript for factual accuracy. Although Jazz Pharmaceuticals was involved in the review of the manuscript, the content of this manuscript, the ultimate interpretation, and the decision to submit it for publication in Drugs was made by the authors independently.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"L. Pagano is a board member of Basilea, Cidara Therapeutics, Gilead Sciences, Janssen, Jazz Pharmaceuticals, MSD, Novartis, Pfizer, and Stemline Therapeutics; a consultant for Cidara Therapeutics and Stemline Therapeutics; and has been a speaker for Astellas Pharma, Gilead Sciences, Janssen, Jazz Pharmaceuticals, Kyowa Kirin, MSD, Novartis, and Pfizer. R. Danesi has received speaker\u2019s bureau\/advisor's fees from AstraZeneca, EUSA Pharma, Genzyme, Gilead Sciences, Ipsen, Janssen, Jazz Pharmaceuticals, Lilly, Novartis, Pfizer, and Sanofi. E. Benedetti has received speaker\u2019s bureau\/advisor\u2019s fees from AstraZeneca, BeiGene, and Jazz Pharmaceuticals. R. Morgagni has no conflicts of interest to declare. L. Romani has no conflicts of interest to declare. A. Venditti has received research funding from Jazz Pharmaceuticals; he was a consultant for AbbVie, Amgen, Astellas Pharma, Astex Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, Delbert Pharma, Glycostem, Janssen, Kite-Gilead, Menarini, Novartis, Otsuka, Pfizer, Servier, and Stemline Therapeutics. All are not related to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors were involved in study concept and design and have contributed to discussions around the manuscript content. All authors critically reviewed the manuscript and approved the final version for submission. All authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article and take responsibility for the integrity of the work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}